International Journal of Hematology

, Volume 73, Issue 3, pp 369–377 | Cite as

Long-Term Outcome of Treatment With Protocols AL841, AL851, and ALHR88 in Children With Acute Lymphoblastic Leukemia: Results Obtained by the Kyushu-Yamaguchi Children’s Cancer Study Group

  • Akinobu Matsuzaki
  • Eiichi Ishii
  • Yoshihisa Nagatoshi
  • Haruhiko Eguchi
  • Hiroyuki Koga
  • Fumio Yanai
  • Hiroko Inada
  • Keiko Nibu
  • Yuji Tamai
  • Kensuke Akiyoshi
  • Hideki Nakayama
  • Toshiro Hara
  • Hiromichi Take
  • Sumio Miyazaki
  • Jun Okamura
Case Report


We analyzed the long-term outcome and late effects of treatment in 187 patients with childhood acute lymphoblastic leukemia (ALL) diagnosed between 1984 and 1990. Overall survival and event-free survival rates were 68.2% +- 3.7% and 63.2% +- 3.6% at 15 years, respectively. Of 55 patients who relapsed after achieving the first complete remission (CR), only 17.4% were rescued by salvage therapy. The advantage of stem cell transplantation over chemotherapy was observed only in those patients with bone marrow relapse during therapy. The SD for score height in patients maintaining the first CR significantly decreased at the time of final follow-up compared with that at diagnosis: 0.059 to -0.800 (P < .0001). The decrease was remarkable in patients younger than 5 years at diagnosis. Other late effects included mild liver dysfunction in 18% and hepatitis C virus infection in 9%. Congestive heart failure was observed in only 2.9% of patients despite the high cumulative dose of daunorubicin (450 mg/m2). Although the survival rates of patients on our protocols were comparable to those of other study groups, some modification, including reduction in dose of cranial irradiation and/or anticancer drugs, should be considered to reduce late adverse effects in survivors of childhood ALL.

Key words

Acute lymphoblastic leukemia Child Chemotherapy Growth impairment Late effect 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pui AH, Crist WM. Acute lymphoblastic leukemia. In: Pui CH, ed.Childhood Leukemia. Cambridge, Ma: Cambridge University Press; 1999:288–312.Google Scholar
  2. 2.
    Blatt J, Copeland DR, Bleyer WA. Late effects of childhood cancer and its treatment. In: Pizzo PA, Poplack DG, eds.Principle and Practice of Pediatric Oncology. Philadelphia, Pa: Lippincott-Raven Publishers; 1997:1303–1329.Google Scholar
  3. 3.
    Hudson M. Late complications after leukemia therapy. In: Pui CH, ed.Childhood Leukemia. Cambridge, Ma: Cambridge University Press; 1999:463–481.Google Scholar
  4. 4.
    Matsuzaki A, Ishii E, Okamura J, et al. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children’s Cancer Study Group in Japan.Med Pediatr Oncol. 1996;26:10–19.CrossRefPubMedGoogle Scholar
  5. 5.
    Matsuzaki A, Okamura J, Ishii E, et al. Treatment of standard-risk acute lymphoblastic leukemia in children: the results of protocol AL841 from the Kyushu-Yamaguchi Children’s Cancer Study Group in Japan.Pediatr Hematol Oncol. 1999;16:197–199.CrossRefGoogle Scholar
  6. 6.
    Suwa S,Tachibana K. Standard growth charts for height and weight of Japanese children from birth to 17 years based on a cross-sectional survey of national data.Clin Pediatr Endocrinol. 1993;2:87–97.CrossRefGoogle Scholar
  7. 7.
    Conter V, Arico M, Valsecchi MG, et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster-based intensive chemotherapy.J Clin Oncol. 1995;13:2497–2502.CrossRefPubMedGoogle Scholar
  8. 8.
    Schaison G, Sommelet D, Bancillon A, et al. Treatment of acute lymphoblastic leukemia French protocol Fralle 83-87.Leukemia. 1992;6:148–152.PubMedGoogle Scholar
  9. 9.
    Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X.Lancet. 1995;345:143–148.CrossRefPubMedGoogle Scholar
  10. 10.
    Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86.Blood. 1994;84:3122–3133.PubMedGoogle Scholar
  11. 11.
    Tubergen DG, Gilchrist GS, O’Brien RT, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial irradiation and intrathecal methotrexate and the importance of systemic therapy: a Children’s Cancer Group report.J Clin Oncol. 1993;11:520–526.CrossRefPubMedGoogle Scholar
  12. 12.
    Trueworthy R, Shuster J, Look T, et al. Ploidy of lymphoblast is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study.J Clin Oncol. 1992;10:606–613.CrossRefPubMedGoogle Scholar
  13. 13.
    Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared individualized chemotherapy for childhood acute lymphoblastic leukemia.N Engl J Med. 1998;338:499–505.CrossRefPubMedGoogle Scholar
  14. 14.
    Koizumi S, Fujimoto T, Oka T, et al. Overview of clinical studies of childhood acute lymphoblastic leukemia for more than ten years by the Japanese Children’s Cancer and Leukemia Study Group.Pediatr Hematol Oncol. 1997;14:17–28.CrossRefPubMedGoogle Scholar
  15. 15.
    Smith M,Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.J Clin Oncol. 1996;14:4–6.CrossRefGoogle Scholar
  16. 16.
    Buchanan GR, Rivera GK, Boyett JM, Chauvenet AR, Crist WM, Vietti TJ. Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group study.Blood. 1988;72:1286–1292.PubMedPubMedCentralGoogle Scholar
  17. 17.
    von der Weid N, Wagner B, Angst R, et al. Treatment of relapsing acute lymphoblastic leukemia in childhood. III. Experience with 54 first bone marrow, nine isolated testicular and eight isolated central nervous system relapses observed 1985-1989.Med Pediatr Oncol. 1994;22:361–369.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Henze G, Fengler R, Hartmann R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85): a relapse study of the BFM Group.Blood. 1991;78:1166–1172.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Beyermann B, Adams HP, Henze G. Philadelphia chromosome in relapsed childhood acute lymphoblastic leukemia; a matched pair analysis: Berlin-Frankfurt-Munster Study Group.J Clin Oncol. 1997;15:2231–2237.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Torres A, Alvarez MA, Sanchez J, et al. Allogeneic bone marrow transplantation vs chemotherapy for the treatment of childhood acute lymphoblastic leukaemia in second complete remission.Bone Marrow Transplant. 1999;23:1257–1260.CrossRefPubMedGoogle Scholar
  21. 21.
    Schroeder H, Gustafsson G, Saarinen-Pihkala UM, et al. Allogeneic bone marrow transplantation in second remission of childhood acute lymphoblastic leukaemia: a population-based case control study from the Nordic countries.Bone Marrow Transplant. 1999;23:555–560.CrossRefPubMedGoogle Scholar
  22. 22.
    Ishii E, Miyazaki S, Kai T, Matsuzaki A, Akazawa K, Ueda K. Growth impairment in children with leukemia/lymphoma and solid tumors administered chemotherapy.Int J Pediatr Hematol Oncol. 1995;2:351–356.Google Scholar
  23. 23.
    Clayton PE, Shalet SM, Morris Jones PH, Price DA. Growth in children treated for acute lymphoblastic leukemia.Lancet. 1988;1:460–462.CrossRefPubMedGoogle Scholar
  24. 24.
    Hokken-Koelega ACS, van Doorn JW, Hahlen L, Stijnen T, de Muinck-Schrama SM, Drops SL. Long-term effects of treatment for acute lymphoblastic leukemia with or without cranial irradiation on growth and puberty: a comparative study.Pediatr Res. 1993;33:577–582.CrossRefPubMedGoogle Scholar
  25. 25.
    Sklar C, Mertens A,Walter A, et al. Final height after treatment for childhood acute lymphoblastic leukemia: comparison of no cranial irradiation with 1800 and 2400 centigrays of cranial irradiation.J Pediatr. 1993;123:59–64.CrossRefPubMedGoogle Scholar
  26. 26.
    Groot-Loonen JJ, Otten BJ, van t’Hof MA, Lippens RJ, Stoelinga GB. Chemotherapy plays a major role in the inhibition of catch up growth during maintenance therapy for childhood acute lymphoblastic leukemia.Pediatrics. 1995;96:693–695.PubMedGoogle Scholar
  27. 27.
    Oberfield SE, Allen JC, Pollack J, New MI, Levine LS. Long-term endocrine sequelae after treatment of meduloblastoma: prospective study of growth and thyroid function.J Pediatr. 1986;108:219–223.CrossRefPubMedGoogle Scholar
  28. 28.
    Uruena M, Stanhope R, Chessells JM, Leiper AD. Impaired pubertal growth in acute lymphoblastic leukemia.Arch Dis Child. 1991;66:1403–1407.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Robinson LL, Nesbit ME, Sather HN, Meadows AT, Ortega JA, Hammond GD. Height of children successfully treated for acute lymphoblastic leukemia: a report from the Late Effects Study Committee of Childrens Cancer Study Group.Med Pediatr Oncol. 1985;13:14–21.CrossRefGoogle Scholar
  30. 30.
    Starceski PJ, Lee PA, Blatt J, Finegold D, Brown D. Comparative effect of 1800 and 2400 rad cranial irradiation on height and weight in children treated for acute lymphocytic leukemia.Am J Dis Child. 1987;141:550–552.PubMedGoogle Scholar
  31. 31.
    Stubberfield TG, Byrne GC, Jones TW. Growth and growth hormone secretion after treatment for acute lymphoblastic leukemia in childhood: 18- versus 24-Gy cranial irradiation.J Pediatr Hematol Oncol. 1995;17:167–171.CrossRefPubMedGoogle Scholar
  32. 32.
    Morris MJ.In Vitro Effects of Antileukemia Drugs on Cartilage Metabolism and Their Effects on Somatomedin Production by Liver. Manchester, UK: Manchester University; 1981 [Thesis].Google Scholar
  33. 33.
    Odame I, Reilly JJ, Gibson BE, Donaldson MD. Patterns of obesity in boys and girls after treatment for acute lymphoblastic leukemia.Arch Dis Child. 1994;71:147–149.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Van Dongen-Melman JE, Hokken-Koelega AC, Hahlen K, De Groot A, Tromp CG, Egeler RM. Obesity after successful treatment of acute lymphoblastic leukemia in childhood.Pediatr Res. 1995;38:86–90.CrossRefPubMedGoogle Scholar
  35. 35.
    Didi M, Didcock E, Vavies HA, Ogilvy-Stuart AL, Wales JK, Shalet SM. High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood.J Pediatr. 1995;127:63–67.CrossRefPubMedGoogle Scholar
  36. 36.
    Chlebowski RT, Paroly WS, Pugh RP, et al. Adriamycin given a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity.Cancer Treat Rep. 1980;64:47–51.PubMedGoogle Scholar
  37. 37.
    Neglia JP, Meadow AT, Robinson LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood.N Engl J Med. 1991;325:1220–1228.CrossRefGoogle Scholar
  38. 38.
    Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumours among childhood cancer survivors.Br J Cancer. 1987;56:339–347.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Walter AW, Hancock ML, Pui CH, et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St. Jude Children’s Research Hospital.J Clin Oncol. 1998;16:3761–3767.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2001

Authors and Affiliations

  • Akinobu Matsuzaki
    • 1
    • 2
  • Eiichi Ishii
    • 3
  • Yoshihisa Nagatoshi
    • 4
  • Haruhiko Eguchi
    • 5
  • Hiroyuki Koga
    • 6
  • Fumio Yanai
    • 7
  • Hiroko Inada
    • 5
  • Keiko Nibu
    • 7
  • Yuji Tamai
    • 8
  • Kensuke Akiyoshi
    • 9
  • Hideki Nakayama
    • 10
  • Toshiro Hara
    • 2
  • Hiromichi Take
    • 11
  • Sumio Miyazaki
    • 6
  • Jun Okamura
    • 4
  1. 1.Division of Child HealthSchool of Health Sciences, Kyushu UniversityFukuokaJapan
  2. 2.Department of PediatricsGraduate School of Medical Sciences, Kyushu UniversityFukuokaJapan
  3. 3.Division of PediatricsHamanomachi HospitalFukuokaJapan
  4. 4.Section of PediatricsNational Kyushu Cancer CenterFukuokaJapan
  5. 5.Department of PediatricsKurume UniversityKurumeJapan
  6. 6.Department of PediatricsSaga Medical SchoolSagaJapan
  7. 7.Department of PediatricsFukuoka UniversityFukuokaJapan
  8. 8.Division of PediatricsOita Prefectural HospitalOitaJapan
  9. 9.Department of PediatricsOita Medical UniversityOitaJapan
  10. 10.Division of PediatricsNational Beppu HospitalBeppuJapan
  11. 11.Department of PediatricsKagoshima City HospitalKagoshimaJapan

Personalised recommendations